Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareSource Actemra Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentCareSourcePolicy H4193_MI-SNP-M-4313514

    Actemra Coverage and Prior Authorization

    Customize your policy alerts

    Sign up for CareSource Policy H4193_MI-SNP-M-4313514 alerts

    Get alerted when Policy H4193_MI-SNP-M-4313514 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization criteria for Actemra intravenous and subcutaneous products under CareSource Medicare Advantage, including approved inflammatory and autoimmune indications.

    Policy Summary
    PayerCareSource
    PolicyActemra Coverage and Prior Authorization
    Policy CodePolicy H4193_MI-SNP-M-4313514
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit the diagnosis, concurrent medications, and previous drugs tried.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Actemra formulations covered
    End of plan yearCoverage duration
    18+Minimum initial age for RA and GCA
    2+Minimum initial age for PJIA and SJIA
    1Prerequisite therapy required

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    PreferredPreferred tocilizumab product

    Medical Necessity and Product Coverage Criteria

    Initial therapy — rheumatoid arthritis

    Covered for initial therapy when either pathway is met.

    Rheumatoid arthritis

    • Qualifying prior therapy: Tried Enbrel, a preferred adalimumab product, Rinvoq, or tofacitinib/tofacitinib XR; specified alternative trials may also count.One prior qualifying drug

      Preferred products include Hadlima and Simlandi.

    • Clinical exception: Heart failure or previously treated lymphoproliferative disorder.

    Initial therapy — polyarticular juvenile idiopathic arthritis

    Covered for initial therapy when either pathway is met.

    Polyarticular juvenile idiopathic arthritis

    • Qualifying prior therapy: Tried Enbrel, Rinvoq, tofacitinib, or a preferred adalimumab product; specified alternative trials may also count.
    • Clinical exception: Heart failure or previously treated lymphoproliferative disorder.

    Initial therapy — systemic-onset juvenile idiopathic arthritis

    Covered for initial therapy.

    Systemic-onset juvenile idiopathic arthritis: Patient has systemic-onset juvenile idiopathic arthritis.

    Initial therapy — giant cell arteritis

    Covered for initial therapy when the criterion is met.

    Giant cell arteritis: Tried or is currently taking a systemic corticosteroid, or corticosteroid therapy is contraindicated.

    Initial therapy — systemic-sclerosis-associated interstitial lung disease

    Covered for initial therapy when both criteria are met.

    Systemic-sclerosis-associated interstitial lung disease

    • Acute-phase reactants are elevated.Elevated
    • Diagnosis is confirmed by high-resolution computed tomography.Confirmed by HRCT

    Continuation therapy — all indications

    Continuation therapy applies to all indications.

    Continuation therapy: Patient meets the continuation-therapy requirements for the applicable indication.

    The specific continuation criterion is not provided in this source window.

    Avonex

    Covered when specialist involvement is documented and no concurrent MS disease-modifying agent is used.

    Avonex: Relapsing MS, including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease; prescribed by or after consultation with a neurologist or MS specialist; no concurrent MS disease-modifying agent.

    Authorization duration is 1 year.

    Ayvakit

    Covered when the applicable disease, mutation, platelet, and prior-treatment criteria are met.

    Ayvakit indications: GIST with PDGFRA exon 18 mutation or after two specified prior therapies; PDGFRA D842V myeloid/lymphoid neoplasm with eosinophilia; or systemic mastocytosis meeting subtype and platelet criteria.Platelets ≥50,000/mcL for systemic mastocytosis

    Age 18 years and older; 1-year authorization.

    Balversa

    Covered for specified advanced or metastatic cancers with required FGFR alteration and treatment history.

    Balversa indications: FGFR3-altered locally advanced or metastatic urothelial carcinoma after progression on prior therapy; FGFR-altered locally advanced, recurrent, or metastatic pancreatic adenocarcinoma as subsequent single-agent therapy; or metastatic FGFR-altered NSCLC.

    Age 18 years and older; prerequisite therapy required.

    Benlysta

    Covered when the applicable SLE or lupus-nephritis pathway is met.

    Benlysta indications: Biopsy-confirmed lupus nephritis with concurrent immunosuppressive therapy; continuation with concurrent immunosuppression and response; or autoantibody-positive SLE with standard therapy unless significant toxicity prevents it.

    No concurrent biologic or Lupkynis; age 5 years and older initially.

    Benlysta IV

    Covered when the applicable initial or continuation pathway is met.

    Benlysta IV indications: Biopsy-confirmed lupus nephritis with concurrent immunosuppressive therapy; continuation with response; or autoantibody-positive SLE with standard therapy unless significant toxicity prevents it.

    SLE initial authorization is 4 months; lupus-nephritis initial authorization is 6 months.

    Besremi

    Covered for FDA-approved indications when specialist oversight and nonconcomitant use are documented.

    Besremi: Covered diagnosis documented; prescribed by or in consultation with an oncologist or hematologist; no concomitant interferon product.Age 18 years and older

    Betaseron/Extavia

    Covered for relapsing MS with specialist oversight and no concurrent MS disease-modifying agent.

    Betaseron/Extavia: Relapsing MS, including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease; neurologist or MS-specialist involvement; no concurrent MS disease-modifying agent.

    Authorization duration is 1 year.

    Bexarotene oral

    Covered for FDA-approved indications with specialist involvement.

    Oral bexarotene: Diagnosis is documented and prescribing is by or in consultation with an oncologist or dermatologist.

    Bexarotene topical

    Covered when the disease-specific indication is met.

    Topical bexarotene: Cutaneous T-cell lymphoma with cutaneous lesions; symptomatic smoldering adult T-cell leukemia/lymphoma as first-line therapy; or primary cutaneous marginal-zone or follicle-center lymphoma treated with skin-directed therapy.

    Bizengri

    Covered for specified NRG1 fusion-positive advanced cancers.

    Bizengri: Advanced, unresectable, or metastatic NRG1 fusion-positive cholangiocarcinoma; or NRG1 fusion-positive NSCLC or pancreatic adenocarcinoma after at least one systemic regimen.Age 18 years and older

    Blenrep

    Covered when all prior-treatment and combination requirements are met.

    Blenrep: At least two prior systemic lines; prior exposure to a proteasome inhibitor and an immunomodulatory drug; and combination use with bortezomib and dexamethasone.At least 2 prior systemic lines

    Boniva injection

    Covered for postmenopausal osteoporosis when at least one pathway is met.

    Boniva injection: T-score ≤−2.5; osteoporotic or fragility fracture; or osteopenia with high fracture risk plus inadequate response, fracture, intolerance, inability to take oral therapy, or prior IV bisphosphonate use.T-score ≤−2.5, or −1.0 to −2.5 with qualifying pathway

    Bosentan/ambrisentan

    Covered when diagnostic and prerequisite criteria are met.

    Bosentan/ambrisentan: WHO Group 1 PAH confirmed by right-heart catheterization; or CTEPH treated with bosentan after Adempas trial, Adempas contraindication, or existing bosentan therapy.

    PAH requires cardiologist or pulmonologist involvement.

    Bosulif

    Covered when diagnosis, age, biomarker, and treatment-history requirements are met.

    Bosulif: Ph-positive or BCR::ABL1-positive CML; Ph-positive ALL after at least one other TKI; or myeloid/lymphoid neoplasm with eosinophilia.

    Prerequisite therapy required.

    Braftovi

    Covered for specified BRAF-mutated cancers.

    Braftovi: Unresectable advanced or metastatic BRAF V600 melanoma; BRAF V600E colorectal or rectal cancer with required cetuximab or panitumumab pathway; BRAF V600E recurrent, advanced, or metastatic NSCLC with Mektovi; or BRAF V600E advanced or metastatic appendiceal adenocarcinoma with cetuximab or panitumumab.

    Bosutinib

    Covered for the specified leukemia diagnoses and treatment history.

    Bosutinib: Ph-positive or BCR::ABL1-positive CML; or Ph-positive ALL after at least one other TKI.

    Braftovi

    Covered when disease, mutation, and combination requirements are met.

    Braftovi: BRAF V600-positive melanoma, colorectal or rectal cancer, NSCLC, or appendiceal adenocarcinoma meeting the applicable disease-stage and combination requirements.BRAF V600/V600E mutation

    Briumvi

    Covered for qualifying relapsing MS with specialist oversight.

    Briumvi: Relapsing MS, including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease; neurologist or MS-specialist involvement; no concurrent MS disease-modifying agent.Age 18 years and older

    Brukinsa

    Covered when diagnosis-specific prior therapy or combination criteria are met.

    Brukinsa: Qualifying follicular, mantle-cell, marginal-zone, hairy-cell, primary CNS, CLL/SLL, or Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma meeting the applicable prior-regimen or combination requirement.

    Byooviz

    Covered for listed FDA-approved or medically accepted ophthalmic indications.

    Byooviz: Requested indication is FDA-approved or medically accepted; listed uses include retinopathy of prematurity, diabetic retinopathy, and diabetic macular edema.

    Cinryze

    Covered for HAE prophylaxis when the applicable diagnostic or response pathway is met.

    Cinryze: Initial type I or II HAE with functional C1-INH <50% and low baseline C4; continuation with type I or II HAE and favorable response; or type III HAE with normal C1-INH.Functional C1-INH <50% of normal

    Cablivi

    Covered when all acute TTP conditions are met.

    Cablivi: Acquired TTP; inpatient initiation with plasma exchange; current immunosuppressive therapy; and no more than two prior Cablivi courses.Age 12 years and older

    Cabometyx

    Covered when the indication-specific disease and treatment criteria are met.

    Cabometyx: Qualifying renal, hepatic, bone, thyroid, endometrial, GIST, RET-positive NSCLC, neuroendocrine, adrenocortical, or pheochromocytoma/paraganglioma indication meeting the stated disease-stage and prior-therapy requirements.

    Calquence

    Covered for listed lymphoid malignancies when the applicable prior-treatment or combination criterion is met.

    Calquence: CLL/SLL; mantle-cell lymphoma meeting prior-regimen, inability-to-treat, or rituximab-combination criteria; marginal-zone lymphoma after a systemic regimen; or Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma after a systemic regimen.

    Camzyos Initial Therapy

    Initial therapy requires all listed clinical and cardiac criteria.

    Camzyos initial therapy: At least one obstructive HCM symptom; NYHA class II or III heart failure; qualifying LV hypertrophy; and peak LVOT gradient ≥50 mmHg.Wall thickness ≥15 mm, or ≥13 mm with familial HCM; LVOT gradient ≥50 mmHg

    Camzyos Continuation Therapy

    Continuation requires duration, symptoms, cardiac function, and response.

    Camzyos continuation therapy: Established therapy for at least 8 months; current or prior obstructive HCM symptom and NYHA class II or III heart failure; current LVEF ≥50%; and objective benefit or stabilization/improvement of symptoms.LVEF ≥50%; therapy ≥8 months

    Caprelsa

    Covered for listed FDA-approved or medically accepted indications.

    Caprelsa: Requested indication is FDA-approved or medically accepted, including differentiated thyroid cancer as listed.

    Carglumic Acid

    Covered when the metabolic diagnosis and acute-treatment requirements are met.

    Carglumic acid: N-acetylglutamate synthase deficiency confirmed by mutation or hyperammonemia; or acute propionic/methylmalonic acidemia with ammonia-lowering therapy.Plasma ammonia ≥50 micromol/L for acute PA/MMA

    Cayston

    Covered when airway culture confirms the target organism.

    Cayston: Pseudomonas aeruginosa is identified in an airway culture.

    Ceprotin

    Covered when severe protein C deficiency and related symptoms are documented.

    Ceprotin: Severe protein C deficiency confirmed by low activity, low antigen, or biallelic pathogenic PROC variants; acquired causes excluded; and current or prior purpura fulminans or thromboembolism.

    Cosentyx initial and continuation therapy

    Covered for listed Cosentyx IV indications when applicable criteria are met.

    Non-radiographic axial spondyloarthritis: Objective inflammation is documented.CRP above laboratory ULN or sacroiliitis on MRI

    Initial therapy requires age 18 years and older; continuation requires benefit.

    Cotellic oncology criteria

    Covered for specified melanoma, CNS cancer, and histiocytic-neoplasm indications.

    Cotellic: BRAF V600-positive unresectable, advanced, or metastatic melanoma or specified CNS cancer with required Zelboraf combination; or Langerhans cell histiocytosis, Erdheim-Chester disease, or Rosai-Dorfman disease.

    Crysvita XLH criteria

    Covered for XLH when both diagnostic components are met.

    X-linked hypophosphatemia: Baseline serum phosphorus is below the age-normal range and either baseline TmP/GFR is below the age- and gender-normal range or genetic testing confirms a pathogenic PHEX variant.Low baseline serum phosphorus and low TmP/GFR or pathogenic PHEX variant

    Crysvita TIO criteria

    Covered for tumor-induced osteomalacia when all criteria are met.

    Tumor-induced osteomalacia: Mesenchymal tumor cannot be curatively resected or localized; signs or symptoms of TIO; and low baseline serum phosphorus and TmP/GFR.Serum phosphorus and TmP/GFR below applicable normal range

    Cystaran criteria

    Covered when corneal cysteine crystal deposits are confirmed.

    Cystaran: Corneal cysteine crystal deposits are confirmed by slit-lamp examination.

    Cystagon criteria

    Covered when nephropathic cystinosis is confirmed.

    Cystagon: Biallelic pathogenic or likely pathogenic CTNS variants are confirmed, or white-blood-cell cystine exceeds the normal reference range.

    Dalfampridine criteria

    Initial and continuation therapy require ambulation and MS-related mobility benefit.

    Dalfampridine: Initial: patient is ambulatory, has MS-related impaired ambulation documented objectively, and treatment is to improve or maintain mobility. Continuation: patient remains ambulatory and responds to or benefits from therapy.

    Datroway criteria

    Covered for specified breast cancer and EGFR-mutated NSCLC pathways.

    Datroway: Unresectable or metastatic HER2-negative breast cancer meeting the hormone-receptor and prior-treatment pathway; or locally advanced/metastatic EGFR-mutated NSCLC after at least one EGFR-directed treatment.

    The visible NSCLC criterion is incomplete.

    Deferasirox criteria

    Covered for specified chronic iron-overload conditions and continuation benefit.

    Deferasirox: Regular transfusions with ferritin >1,000 mcg/L; non-transfusion-dependent thalassemia with ferritin >300 mcg/L; or continuation with prescriber-confirmed benefit.Ferritin >1,000 or >300 mcg/L, respectively

    Deferiprone criteria

    Covered for chronic transfusion-related iron overload; continuation requires benefit.

    Deferiprone: Chronic transfusion-related iron overload due to thalassemia syndrome, sickle cell disease, or another anemia; or continuation with documented benefit.

    Diabetic supplies

    Covered when the supply is directly associated with insulin delivery.

    Diabetic supplies: Prescriber confirms that alcohol pads, gauze pads, pen needles, or insulin syringes are requested for use directly associated with delivering insulin.

    Doptelet chronic ITP initial therapy

    Chronic ITP initial therapy requires both platelet and prior-treatment criteria.

    Chronic ITP initial therapy

    • Platelet count <30,000/mcL, or <50,000/mcL with increased bleeding risk.
    • Tried another listed therapy or had a splenectomy.

    Doptelet continuation therapy

    Continuation requires beneficial response and ongoing bleeding risk.

    Doptelet continuation: Beneficial clinical response and continued risk for bleeding complications.

    Dupixent initial therapy

    Covered for the applicable disease-specific Dupixent indication.

    Dupixent initial therapy: Atopic dermatitis; asthma meeting eosinophil, controller-treatment, and uncontrolled-disease criteria; COPD meeting eosinophil, combination-therapy, and exacerbation criteria; CRSwNP; EoE; or AFRS meeting the detailed policy criteria.

    Dupixent continuation therapy

    Continuation requires the applicable treatment duration and clinical response.

    Dupixent continuation: Patient has received the required duration and demonstrates indication-specific benefit, with required concurrent therapy where specified.Generally at least 6 months for listed indications

    Emgality coverage

    Covered for migraine prevention or episodic cluster headache.

    Emgality: Migraine prevention with at least 4 migraine days per month and significant benefit if already treated; or episodic cluster headache with one headache every other day to eight headaches per day.≥4 migraine days/month

    Erlotinib indications

    Covered for the listed erlotinib indications.

    Erlotinib: EGFR-positive advanced/metastatic NSCLC; qualifying non-clear-cell RCC with bevacizumab; chordoma after prior therapy; locally advanced/metastatic/recurrent pancreatic cancer with gemcitabine; or advanced/recurrent/metastatic vulvar cancer.

    Everolimus indication-specific criteria

    Covered when the indication-specific everolimus criteria are met.

    Everolimus: Qualifying breast, renal, TSC, thyroid, endometrial, GIST, neuroendocrine, PEComa, lymphoma, histiocytic-neoplasm, meningioma, or uterine-sarcoma indication with required biomarker, combination, and prior-treatment criteria.

    Fabrazyme diagnostic criteria

    Covered when laboratory or molecular testing confirms Fabry disease.

    Fabrazyme: Deficient alpha-galactosidase A activity in leukocytes or fibroblasts, or a pathogenic galactosidase alpha gene variant.

    Fasenra initial asthma therapy

    Initial asthma therapy requires all listed criteria.

    Fasenra asthma: Eosinophils ≥150 cells/mcL; prior ICS plus another controller; and uncontrolled asthma demonstrated by qualifying exacerbation, pulmonary-function abnormality, or worsening during steroid taper.Eosinophils ≥150 cells/mcL; FEV1 <80% predicted or FEV1/FVC <0.80

    Fasenra initial EGPA therapy

    Initial EGPA therapy requires all listed criteria.

    Fasenra EGPA: Active, non-severe EGPA; systemic corticosteroid use for at least 4 weeks; and pretreatment eosinophil measurement before a monoclonal antibody that may alter eosinophils.

    Fasenra continuation therapy

    Continuation is supported by clinical benefit.

    Fasenra continuation: Clinical benefit may include reduced fatigue, reduced corticosteroid requirements, or decreased eosinophil levels.

    Fintepla initial therapy

    Initial therapy requires the applicable epilepsy syndrome and antiseizure-treatment history.

    Fintepla initial therapy: Dravet syndrome with at least two other antiseizure drugs, or Epidiolex, clobazam, or Diacomit; or Lennox-Gastaut syndrome with at least two other antiseizure drugs.Age 2 years and older

    Fintepla continuation therapy

    Continuation requires response.

    Fintepla continuation: Patient is responding to therapy for Dravet syndrome or Lennox-Gastaut syndrome.

    Fotivda renal cell carcinoma

    Covered for qualifying relapsed or stage IV renal cell carcinoma.

    Fotivda: Relapsed or stage IV renal cell carcinoma and at least two prior systemic regimens.At least 2 prior regimens

    Fruzaqla colorectal, rectal, or appendiceal cancer

    Covered when all disease and prior-treatment criteria are met.

    Fruzaqla: Advanced or metastatic colorectal, rectal, or appendiceal cancer; applicable MMR/MSI or checkpoint-inhibitor criterion; prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and anti-VEGF therapy; and applicable anti-EGFR pathway for RAS wild-type disease.

    Fulphila chemotherapy indication

    Covered when one chemotherapy-related neutropenia pathway is met.

    Fulphila: Myelosuppressive regimen with febrile-neutropenia risk ≥20%; lower-risk regimen with prescriber-identified risk factors; or prior neutropenic complication without prophylaxis and dose reduction.Febrile-neutropenia risk ≥20%

    Fyарro malignant PEComa

    Covered for the listed malignant PEComa indication.

    Fyарro: Patient has locally advanced malignant perivascular epithelioid cell tumor; the visible source criterion is incomplete.

    Fyarrо initial therapy

    Covered when all applicable criteria are met.

    Fyarrо: Age 18 years and older; locally advanced malignant PEComa; and prescribing by or in consultation with an oncologist.

    Gattex initial therapy

    Covered when all applicable criteria are met.

    Gattex initial therapy: Age 1 year or older; gastroenterologist involvement; and parenteral nutrition on at least 3 days per week or inability to receive adequate total parenteral nutrition.Parenteral nutrition ≥3 days/week

    Gavreto RET-altered malignancies

    Covered for qualifying RET-altered cancers.

    Gavreto: RET fusion-positive advanced/recurrent/metastatic NSCLC; RET-altered unresectable/recurrent/metastatic differentiated thyroid cancer meeting systemic-therapy and radioactive-iodine criteria; or RET-pathogenic-variant anaplastic or medullary thyroid cancer.

    EGFR-directed therapy and additional Gilotrif indications

    Covered when molecular testing and disease-status criteria are met.

    EGFR-directed therapy: Advanced/metastatic sensitizing EGFR-mutation-positive NSCLC; metastatic squamous NSCLC after platinum chemotherapy; or non-nasopharyngeal head-and-neck cancer progressing on or after platinum chemotherapy.

    Relapsing multiple sclerosis

    Covered for relapsing MS with specialist involvement.

    Glatiramer or Glatopa: Relapsing MS, including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease; neurologist or MS-specialist involvement; no concurrent MS disease-modifying agent.

    Zoladex diagnosis-specific coverage

    Covered for the applicable diagnosis and product strength.

    Zoladex: Abnormal uterine bleeding with 3.6 mg before endometrial ablation; endometriosis with 3.6 mg; prostate cancer with 3.6 mg and/or 10.8 mg; or other listed FDA-approved or medically accepted oncology use.

    Neurofibromatosis type 1

    Covered when all criteria are met.

    Gomekli: Age 2 years and older; symptomatic plexiform neurofibromas associated with NF1; tumor is not amenable to complete resection.

    Oncology GnRH agonists

    Covered for qualifying oncology indications.

    Oncology GnRH agonists: Qualifying FDA-approved or medically accepted oncology indication; head-and-neck salivary-gland tumors must be recurrent, unresectable, or metastatic and androgen-receptor-positive.

    Growth hormone initial and continuation therapy

    Covered when the applicable diagnosis-specific criteria are met.

    Growth hormone: Qualifying growth hormone deficiency, idiopathic short stature, small for gestational age, CKD, Noonan syndrome, Prader-Willi syndrome, SHOX deficiency, Turner syndrome, or short bowel syndrome pathway; continuation requires documented response where specified.Pediatric stimulation tests <10 ng/mL; diagnosis-specific growth and laboratory thresholds apply

    HER2-mutated NSCLC

    Covered when all criteria are met.

    Hernexeos: Age 18 years and older; unresectable or metastatic NSCLC; activating HER2/ERBB2 mutation.

    HERNEXEOS initial therapy

    Covered when both disease criteria are met.

    HERNEXEOS: Unresectable or metastatic NSCLC and activating HER2/ERBB2 mutation.

    HYRNUO initial therapy

    Covered when all criteria are met.

    HYRNUO: Locally advanced or metastatic NSCLC; activating HER2/ERBB2 mutation; and at least one prior systemic therapy.

    IBRANCE breast cancer

    Covered when all breast-cancer criteria are met.

    IBRANCE: Locally advanced, recurrent, or metastatic hormone-receptor-positive disease; HER2-negative disease or HER2-positive disease with trastuzumab; and applicable menopausal, ovarian-suppression, and endocrine-combination requirements.

    IBTROZI initial therapy

    Covered when both criteria are met.

    IBTROZI: Locally advanced or metastatic NSCLC and ROS1-positive disease detected by an approved test.

    Icatibant initial and continuation therapy

    Covered for the listed hereditary angioedema indications.

    Icatibant: Type I or II HAE with low functional C1-INH and low C4; prior favorable response to icatibant for acute attacks; or type III HAE with normal C1-INH.Functional C1-INH <50% for diagnostic pathway

    ICLUSIG initial therapy

    Covered when one applicable disease pathway is met.

    ICLUSIG: Qualifying Ph-positive/ABL-class ALL; Ph-positive/BCR::ABL1-positive CML; GIST after required prior therapies; or ABL1/FGFR1-rearranged myeloid/lymphoid neoplasm with eosinophilia.

    IDHIFA initial therapy

    Covered when both criteria are met.

    IDHIFA: Acute myeloid leukemia and IDH2 mutation-positive status detected by an approved test.

    High-risk medication criteria

    For patients aged 65 years and older, the medication-specific criteria and risk-benefit assessment must be met.

    High-risk medication review: Prescriber assessed risks and benefits and confirms the desire to initiate or continue the requested medication.Age 65 years and older

    Initial Therapy Requirements

    Benlysta initial therapy

    Initial Benlysta therapy requires diagnosis-specific clinical evidence.

    Benlysta initial therapy: Biopsy-confirmed lupus nephritis with concurrent immunosuppressive regimen; or autoantibody-positive SLE with concurrent standard therapy unless significant toxicity makes it intolerable.

    Cinryze Initial Therapy

    Initial Cinryze prophylaxis requires confirmed HAE and qualifying baseline laboratory results.

    Cinryze initial therapy: Type I or II HAE confirmed by functional C1-INH below 50% of normal and lower-than-normal baseline C4.Functional C1-INH <50%

    Camzyos Initial Therapy

    Initial Camzyos therapy requires all specified criteria.

    Continuation and Reauthorization Requirements

    Benlysta continuation

    Continuation requires ongoing qualifying therapy and clinical response.

    Benlysta continuation: Lupus nephritis: ongoing immunosuppressive regimen and response; or SLE: ongoing standard therapy unless significant toxicity prevents it.

    Cinryze Continuation

    Continuation is covered when type I or II HAE and favorable response are documented.

    Cinryze continuation: Type I or II HAE and favorable clinical response compared with baseline.

    Camzyos Continuation

    Continuation requires all specified duration, cardiac, and response criteria.

    Prerequisite and Step-Therapy Requirements

    Drug/indicationRequired prior therapyAlternative pathway or notes
    Actemra — rheumatoid arthritis
    Try one prior qualifying therapy: Enbrel, preferred adalimumab product, Rinvoq, or tofacitinib/tofacitinib XR. Trials of Cimzia, Kevzara, infliximab, golimumab, Orencia, or a non-preferred adalimumab product also count.
    Heart failure or previously treated lymphoproliferative disorder may satisfy the requirement. Preferred adalimumab products include Hadlima and Simlandi.
    Drug/indicationRequired prior therapyAlternative pathway or notes
    Actemra — polyarticular juvenile idiopathic arthritis
    Try one prior qualifying therapy: Enbrel, Rinvoq, tofacitinib, or preferred adalimumab product. Trials of Kevzara, infliximab, Orencia, or a non-preferred adalimumab product also count.
    Heart failure or previously treated lymphoproliferative disorder may satisfy the requirement. Initial therapy applies to patients age 2 years and older.
    Drug/indicationRequired prior therapyAlternative pathway or notes
    Actemra — giant cell arteritis
    Try or currently take a systemic corticosteroid.
    The requirement may be met when systemic corticosteroid therapy is contraindicated. Initial therapy applies to patients age 18 years and older.
    Drug/indicationRequired prior therapyAlternative pathway or notes
    Ayvakit — GIST
    Try two of Gleevec (imatinib), Sutent (sunitinib), Sprycel (dasatinib), Stivarga (regorafenib), or Qinlock (ripretinib).
    Prior therapy is not required when the tumor has a PDGFRA exon 18 mutation.
    Drug/indicationRequired prior therapyAlternative pathway or notes
    Balversa — urothelial carcinoma
    Use after progression during or following prior platinum-containing chemotherapy, other chemotherapy, or checkpoint inhibitor therapy.
    Disease must be locally advanced or metastatic and have a susceptible FGFR3 alteration.
    Drug/indicationRequired prior therapyAlternative pathway or notes
    Bizengri — NSCLC or pancreatic adenocarcinoma
    Try at least one systemic regimen.
    Disease must be advanced, unresectable, or metastatic and NRG1 fusion-positive. Examples include platinum or PD-1/PD-L1 therapy for NSCLC and fluorouracil, leucovorin, irinotecan, oxaliplatin, gemcitabine, paclitaxel, or capecitabine for pancreatic cancer.
    Drug/indicationRequired prior therapyCombination requirement
    Blenrep — multiple myeloma
    Try at least two prior systemic lines, including at least one proteasome inhibitor and one immunomodulatory drug.
    Use in combination with bortezomib and dexamethasone.
    Drug/indicationRequired prior therapyAlternative pathway or notes
    Boniva injection — postmenopausal osteoporosis
    A qualifying pathway includes inadequate response after a 12-month oral bisphosphonate trial, fracture during oral therapy, or oral bisphosphonate intolerance.
    Oral therapy may be bypassed when the patient cannot swallow or remain upright, has a qualifying gastrointestinal condition, or has tried an IV bisphosphonate. Authorization is 12 months.
    Drug/indicationRequired prior therapyAlternative pathway or notes
    Bosentan — chronic thromboembolic pulmonary hypertension
    Try Adempas.
    A contraindication to Adempas or current bosentan treatment for CTEPH also satisfies the pathway.
    Drug/indicationRequired prior therapyAlternative pathway or notes
    Bosulif — Philadelphia chromosome-positive ALL
    Try at least one other tyrosine kinase inhibitor.
    The requirement applies to Philadelphia chromosome-positive ALL; other Bosulif indications have separate criteria.
    Drug/indicationRequired prior therapyCombination requirement
    Braftovi — colorectal or rectal cancer
    For the later-line pathway, receive prior chemotherapy for colorectal or rectal cancer.
    Use with Erbitux or Vectibix. First-line metastatic therapy requires FOLFOX plus cetuximab or panitumumab; later-line therapy requires prior chemotherapy plus cetuximab or panitumumab.
    Drug/indicationRequired prior therapyAlternative pathway or notes
    Bosutinib — Philadelphia chromosome-positive ALL
    Try at least one other tyrosine kinase inhibitor.
    The requirement applies to Philadelphia chromosome-positive ALL. Authorization duration is 12 months.
    Drug/indicationRequired prior therapyCombination requirement
    Brukinsa
    Prior systemic regimens are required for follicular, mantle cell, marginal zone, hairy cell, and primary CNS lymphomas as specified by subtype.
    Some pathways require combination therapy, including Gazyva, rituximab, Venclexta plus Gazyva, or autologous stem-cell reinfusion.
    Drug/indicationRequired prior therapyAlternative pathway or notes
    Cabometyx
    Prior systemic therapy is required for hepatocellular carcinoma, bone cancer, thyroid carcinoma, endometrial carcinoma, and GIST. GIST requires two listed prior agents.
    For RET-positive NSCLC, disease must have progressed on Gavreto or Retevmo. Other indications have disease-specific criteria.
    Drug/indicationRequired prior therapyAlternative pathway or notes
    Calquence — specified lymphomas
    Try at least one prior systemic regimen for mantle cell lymphoma, marginal zone lymphoma, or Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma.
    An allowed alternative, such as inability to receive systemic therapy or combination with rituximab for mantle cell lymphoma, may satisfy the requirement.
    Drug/indicationRequired prior therapyAlternative pathway or notes
    Datroway — EGFR-mutated locally advanced or metastatic NSCLC
    Try at least one prior EGFR-directed therapy.
    The visible criteria also require EGFR-mutated disease. Additional criteria may apply.
    Drug/indicationRequired prior therapyAlternative pathway or notes
    Doptelet — chronic immune thrombocytopenia
    Try one other therapy, such as systemic corticosteroids, IVIG, anti-D immunoglobulin, eltrombopag, romiplostim, fostamatinib, or rituximab.
    A prior splenectomy may satisfy the requirement. Platelet thresholds also apply.
    Drug/indicationRequired prior therapyDuration
    Dupixent — eosinophilic esophagitis
    Use prescription-strength proton pump inhibitor therapy.
    PPI therapy is required for at least 8 weeks.
    Drug/indicationRequired prior therapyDuration
    Dupixent — COPD
    Receive combination therapy with at least two of LAMA, LABA, or ICS.
    Combination therapy is required for at least 3 months.
    Drug/indicationRequired prior therapyRequired drug classes
    Elrexfio — multiple myeloma
    Receive at least four prior systemic regimens.
    Prior regimens must include the required drug classes, including a proteasome inhibitor and other classes specified in the policy.
    Drug/indicationRequired prior therapyAlternative pathway or notes
    Fintepla — Dravet syndrome or Lennox-Gastaut syndrome
    Try or concomitantly receive at least two other antiepileptic drugs. For Dravet syndrome, Epidiolex, clobazam, or Diacomit may also satisfy the pathway.
    Initial therapy applies to patients age 2 years and older.
    Drug/indicationRequired prior therapyAlternative pathway or notes
    Firmagon — new-to-therapy patients
    Try Eligard before Firmagon approval.
    The requirement applies to patients new to Firmagon therapy.
    Drug/indicationRequired prior therapyDisease requirement
    Fotivda — renal cell carcinoma
    Try at least two other systemic regimens.
    Disease must be relapsed or stage IV renal cell carcinoma.
    Drug/indicationRequired prior therapyAdditional requirement
    Fruzaqla — colorectal, rectal, or appendiceal cancer
    Prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy plus an anti-VEGF agent.
    For RAS wild-type disease, receive anti-EGFR therapy or have documentation that it is not medically appropriate. Advanced or metastatic disease and applicable MMR/MSI criteria also apply.
    Drug/indicationRequired prior therapyNotes
    Gattex — short bowel syndrome
    Prerequisite therapy is required.
    The specific prerequisite is not stated in the available policy section.
    Drug/indicationRequired stepNotes
    Gilotrif — MA-PD beneficiaries
    Part B coverage must be considered before Part D coverage; prerequisite therapy is also required.
    The Part B-before-Part D step applies only to beneficiaries enrolled in an MA-PD plan.
    Drug/indicationRequired prior therapyAlternative pathway or notes
    ICLUSIG — gastrointestinal stromal tumor
    Try imatinib or Ayvakit, sunitinib or Sprycel, Stivarga, and Qinlock.
    For selected leukemia indications, prior tyrosine kinase inhibitor therapy may satisfy an alternative criterion; molecular and disease-phase criteria also apply.
    Medication/indicationRequired prior therapyAdditional requirement
    Lorazepam — insomnia
    Try two of ramelteon, doxepin 3 mg or 6 mg, eszopiclone, zolpidem, or zaleplon.
    The prescriber must assess risk versus benefit and confirm the desire to initiate or continue therapy.

    Authorization, Documentation, and Denial Risks

    Denial Risk

    Concurrent Biologic, DMARD, and Monoclonal-Antibody Therapy

    For biologic and targeted therapies, verify the diagnosis, prior therapies, prescriber specialty, concurrent medications, and continuation response before submitting authorization. Denials may result from concurrent biologic, targeted synthetic DMARD, monoclonal-antibody, JAK-inhibitor, or other prohibited therapy.

    • ACTEMRA: document diagnosis, concurrent medications, and previous drugs tried; do not use concurrently with a biologic DMARD or targeted synthetic DMARD.
    • ACTEMRA excludes hospitalized COVID-19 treatment; for initial RA/PJIA therapy, document required prior therapy or qualifying heart failure/previously treated lymphoproliferative disorder.
    • ACTEMRA GCA requires current or prior systemic corticosteroid therapy, or a corticosteroid contraindication; systemic-sclerosis-associated interstitial lung disease requires elevated acute-phase reactants and high-resolution CT confirmation.
    • BENLYSTA: document SLE or biopsy-confirmed lupus nephritis, autoantibody status when applicable, concurrent standard immunosuppressive therapy, and response for continuation; avoid concurrent biologics or Lupkynis.
    • COSENTYX: avoid concurrent biologic or targeted synthetic DMARD use; continuation requires documented benefit.
    • DUPIXENT and related biologics: avoid concurrent monoclonal antibodies and JAK inhibitors; document indication-specific baseline criteria and clinical response.

    Clinical Thresholds and Supporting Values

    Acute-phase reactants
    ThresholdElevated
    Applies toSystemic-sclerosis-associated interstitial lung disease
    DocumentationReport acute-phase reactant results
    Interstitial lung disease diagnosis
    Diagnostic methodConfirmed by high-resolution computed tomography
    Applies toInterstitial lung disease associated with systemic sclerosis
    DocumentationSubmit imaging confirmation

    Definitions and Policy Terms

    Preferred adalimumab product
    Preferred productsHadlima or Simlandi
    Product classAdalimumab products
    Use in policyCounts as a qualifying prior therapy for initial rheumatoid arthritis or polyarticular juvenile idiopathic arthritis therapy
    Initial versus continuation therapy
    Initial therapyApplies to new treatment requests and includes listed age, prescriber, and prerequisite requirements
    Continuation therapyRequires the applicable ongoing-therapy criteria
    Systemic-sclerosis-associated interstitial lung disease

    Policy Background

    Actemra is reviewed for inflammatory and autoimmune conditions, including rheumatoid arthritis, polyarticular and systemic-onset juvenile idiopathic arthritis, giant cell arteritis, and interstitial lung disease associated with systemic sclerosis. Coverage is based on the applicable diagnosis-specific requirements, which may include age, specialist involvement, clinical documentation, and prior therapy.

    Preferred Tocilizumab Products

    Billing Rule

    Use a preferred tocilizumab product

    Actemra and Tyenne are identified as preferred tocilizumab products.

    Policy Summary
    PayerCareSource
    PolicyActemra Coverage and Prior Authorization
    Policy CodePolicy H4193_MI-SNP-M-4313514
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit the diagnosis, concurrent medications, and previous drugs tried.
    SourceLink
    On This Page
    Medical Necessity and Product Coverage CriteriaInitial Therapy RequirementsContinuation and Reauthorization RequirementsPrerequisite and Step-Therapy RequirementsAuthorization, Documentation, and Denial RisksClinical Thresholds and Supporting ValuesDefinitions and Policy TermsPolicy BackgroundPreferred Tocilizumab Products
    Camzyos initial therapy: Obstructive HCM symptom; NYHA class II or III heart failure; qualifying LV hypertrophy; and peak LVOT gradient ≥50 mmHg.Wall thickness ≥15 mm, or ≥13 mm with familial HCM; LVOT gradient ≥50 mmHg

    Cosentyx initial therapy

    Initial Cosentyx therapy requires the age and indication-specific requirements.

    Cosentyx initial therapy: Patient is at least 18 years old and meets the applicable indication-specific criteria.Age ≥18 years

    Dalfampridine initial therapy

    Initial therapy requires ambulation and objective MS-related mobility impairment.

    Dalfampridine initial therapy: Patient is ambulatory, treatment is for MS-related mobility, and impaired ambulation is documented objectively.

    Deferasirox initial therapy

    Initial therapy requires one applicable iron-overload pathway.

    Deferasirox initial therapy: Regular transfusions with ferritin >1,000 mcg/L, or non-transfusion-dependent thalassemia with ferritin >300 mcg/L.Ferritin >1,000 or >300 mcg/L

    Deferiprone initial therapy

    Initial therapy is covered for qualifying chronic transfusion-related iron overload.

    Deferiprone initial therapy: Chronic transfusion-related iron overload due to thalassemia syndrome, sickle cell disease, or another anemia.

    Diacomit initial therapy

    Initial Dravet-syndrome therapy requires the diagnosis and clobazam pathway.

    Diacomit initial therapy: Dravet syndrome and concomitant clobazam use, or inability to take clobazam because of adverse events.Age ≥6 months

    Doptelet initial therapy

    Initial therapy requires the applicable indication-specific pathway.

    Doptelet initial therapy: Chronic liver disease thrombocytopenia with platelets <50 × 10^9/L and a procedure in 10–13 days; or chronic ITP with platelet threshold and prior therapy or splenectomy.

    Dupixent initial indication criteria

    Initial therapy requires all criteria for the selected indication.

    Dupixent initial therapy: Asthma, COPD, CRSwNP, EoE, or AFRS meeting the disease-specific laboratory, treatment-history, exacerbation, imaging, or biopsy criteria.

    Elahere initial therapy

    Initial therapy requires all listed criteria.

    Elahere initial therapy: Age ≥18 years; folate receptor alpha-positive ovarian, fallopian tube, or primary peritoneal cancer; oncology prescribing or consultation.

    Elaprase initial therapy

    Initial therapy requires laboratory or molecular confirmation.

    Elaprase initial therapy: Deficient iduronate-2-sulfatase activity demonstrated in laboratory testing, or qualifying iduronate-2-sulfatase gene finding.

    Elrexfio initial therapy

    Initial therapy requires multiple myeloma and the specified prior regimens.

    Elrexfio initial therapy: Multiple myeloma; at least four prior systemic regimens; and exposure to the required prior drug classes, including a proteasome inhibitor.At least 4 systemic regimens

    Fasenra initial asthma

    Initial asthma therapy requires all listed conditions.

    Fasenra asthma: Eosinophils ≥150 cells/mcL; ICS plus another controller; and uncontrolled asthma shown by a qualifying exacerbation, pulmonary-function abnormality, or steroid-taper worsening.Eosinophils ≥150 cells/mcL

    Fasenra initial EGPA

    Initial EGPA therapy requires all listed conditions.

    Fasenra EGPA: Active, non-severe EGPA; systemic corticosteroid use for at least 4 weeks; and pretreatment eosinophil measurement.

    Fintepla initial therapy

    Initial therapy requires the applicable syndrome and antiseizure treatment history.

    Fintepla initial therapy: Dravet syndrome with required prior or concomitant antiseizure therapy, or Lennox-Gastaut syndrome with at least two other antiseizure drugs.Age ≥2 years

    Fotivda initial therapy

    Initial therapy requires qualifying relapsed or stage IV RCC and prior treatment.

    Fotivda initial therapy: Relapsed or stage IV renal cell carcinoma and at least two prior systemic regimens.At least 2 prior regimens

    Fruzaqla initial therapy

    Initial therapy requires all listed disease and prior-treatment conditions.

    Fruzaqla initial therapy: Advanced or metastatic colorectal, rectal, or appendiceal cancer; applicable MMR/MSI or checkpoint-inhibitor criterion; prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and anti-VEGF therapy; and applicable anti-EGFR pathway.

    Gattex initial therapy

    Initial approval requires all applicable criteria.

    Gattex initial therapy: Age ≥1 year; gastroenterologist involvement; and parenteral nutrition on at least 3 days per week or inadequate ability to meet caloric needs.Parenteral nutrition ≥3 days/week

    Gavreto initial therapy

    Initial approval requires the applicable RET alteration and disease criteria.

    Gavreto initial therapy: Qualifying RET-altered NSCLC, differentiated thyroid cancer, anaplastic thyroid cancer, or medullary thyroid cancer meeting disease extent and treatment criteria.

    EGFR-directed initial therapy

    Initial approval requires qualifying molecular testing and disease status.

    EGFR-directed initial therapy: Qualifying EGFR-mutated advanced/metastatic NSCLC, or the additional Gilotrif squamous NSCLC or head-and-neck cancer pathway.

    Gomekli initial therapy

    Initial approval requires all criteria.

    Gomekli initial therapy: Age ≥2 years; symptomatic, unresectable plexiform neurofibromas associated with NF1.

    Growth hormone initial therapy

    Initial approval requires the applicable diagnosis-specific criteria.

    Growth hormone initial therapy: Qualifying growth hormone deficiency, idiopathic short stature, CKD, Noonan syndrome, Prader-Willi syndrome, SHOX deficiency, small for gestational age, Turner syndrome, or short bowel syndrome pathway.

    Hernexeos initial therapy

    Initial approval requires all criteria.

    Hernexeos initial therapy: Age ≥18 years; unresectable or metastatic NSCLC; activating HER2/ERBB2 mutation.

    Specialty drug initial therapy

    Initial therapy is covered when product-specific diagnosis, testing, age, specialist, and prior-treatment requirements are met.

    Specialty drug initial therapy: Covered diagnosis and all product-specific clinical criteria in the policy are documented.

    Continuation therapy

    Continuation therapy is evaluated for all indications.

    Continuation therapy: Patient meets the continuation-therapy requirement for the requested indication.

    The specific continuation requirement is incomplete in this source window.

    Camzyos continuation: At least 8 months of established therapy; current or prior obstructive HCM symptom and NYHA II or III heart failure; LVEF ≥50%; and objective benefit or symptom stabilization/improvement.LVEF ≥50%

    Cosentyx continuation

    Continuation is approved when the patient benefits from Cosentyx.

    Cosentyx continuation: Patient has documented benefit from Cosentyx.

    Crysvita continuation

    Continuation is approved when the patient continues to derive benefit.

    Crysvita continuation: Patient continues to derive benefit as determined by the prescribing physician.

    Dalfampridine continuation

    Continuation requires ongoing ambulation and benefit.

    Dalfampridine continuation: Patient remains ambulatory and has responded to or benefits from therapy.

    Iron chelation continuation

    Continuation requires documented benefit.

    Iron chelation continuation: Patient is benefiting from deferasirox or deferiprone therapy.

    Diacomit continuation

    Continuation requires response.

    Diacomit continuation: Patient is responding to Diacomit therapy for Dravet syndrome.

    Doptelet continuation

    Continuation requires ongoing benefit and bleeding risk.

    Doptelet continuation: Beneficial clinical response and continued risk for bleeding complications.

    Dupixent continuation

    Continuation requires the applicable treatment duration and clinical response.

    Dupixent continuation: Required treatment duration completed and beneficial clinical response documented, with concurrent therapy where specified.Generally at least 6 months for listed indications

    Emgality continuation

    Continuation requires significant clinical benefit.

    Emgality continuation: Patient has significant benefit, such as fewer overall or severe migraine days.

    Fintepla continuation

    Continuation requires response.

    Fintepla continuation: Patient is responding to Fintepla therapy.

    Fasenra continuation

    Continuation is based on clinical response or benefit.

    Fasenra continuation: Clinical benefit may include reduced fatigue, reduced corticosteroid requirements, or decreased eosinophil levels.

    Gattex continuation

    Continuation requires improvement.

    Gattex continuation: Patient has experienced improvement with therapy.

    Growth hormone continuation

    Continuation requires documented response or applicable certification.

    Growth hormone continuation: Prescriber confirms response for the applicable indication, or certifies that treatment is not for anti-aging or athletic performance where specified.

    Icatibant continuation

    Continuation requires prior favorable response to icatibant.

    Icatibant continuation: Prior acute type I or II HAE attacks were treated with icatibant and the prescriber documents favorable clinical response.

    High-risk medication continuation

    Continuation requires risk-benefit confirmation and the medication-specific requirement.

    High-risk medication continuation: Prescriber confirms risk-benefit assessment and desire to continue; phenobarbital for seizures additionally requires that the patient is currently taking phenobarbital.
  1. FASENRA: avoid concurrent monoclonal-antibody therapy and submit eosinophil results plus asthma, EGPA, or HES clinical documentation.
  2. Unsupported block type: denial_risk

    Documentation Required

    Hereditary Angioedema Documentation

    Submit complete clinical evidence for hereditary angioedema products, including diagnostic testing, laboratory values, treatment history, and response. The record must support the requested prophylaxis or acute-attack indication.

    • Cinryze prophylaxis: document type I or II HAE, baseline functional C1-INH below 50% of normal, and lower-than-normal baseline C4; for continuation, document favorable clinical response to prophylaxis.
    • Icatibant acute treatment: document type I or II HAE with functional C1-INH below 50% of normal and low baseline C4, or prior icatibant use with favorable response; type III HAE is approved as specified.
    • Use the required allergist/immunologist or HAE-specialist consultation when applicable.
    • Do not substitute an unsupported HAE diagnosis for the required hereditary angioedema diagnostic criteria.

    Unsupported block type: prior_auth

    Unsupported block type: documentation

    Documentation Required

    Rare-Disease and Metabolic Documentation

    For rare-disease and metabolic products, provide specialist documentation, confirmatory laboratory or genetic testing, and relevant response or treatment history. Requests lacking diagnosis and laboratory support are at high risk for denial.

    • Carglumic acid: document N-acetylglutamate synthase deficiency by genetic testing or hyperammonemia; acute propionic or methylmalonic acidemia requires plasma ammonia at least 50 micromol/L and concurrent ammonia-lowering therapy.
    • Cystaran: document corneal cysteine crystal deposits confirmed by slit-lamp examination.
    • Cystagon/Procysbi: document nephropathic cystinosis by CTNS genetic testing or elevated white-blood-cell cystine; do not use Cystagon and Procysbi concurrently.
    • Fabrazyme: document Fabry diagnosis with deficient alpha-galactosidase A activity or pathogenic GLA variant; avoid concurrent Galafold or Elfabrio.
    • Elaprase: submit deficient iduronate-2-sulfatase laboratory testing or molecular confirmation.
    • Cinryze: submit laboratory and clinical response documentation as described in the HAE criteria.

    Unsupported block type: prior_auth

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: step_therapy

    Unsupported block type: prior_auth

    Unsupported block type: documentation

    Unsupported block type: step_therapy

    Note

    Benefit Determination and Continuation Response

    Some products require a benefit determination or coverage-part review in addition to medical-necessity criteria. Include the information needed for CMS Part B versus Part D adjudication and document the expected benefit when continuation criteria apply.

    • BLENREP, DATROWAY, ELREXFIO, FIRMAGON, FYARRO, and ZOLADEX: Part B versus Part D determination is made during prior-authorization review per CMS guidance.
    • Continuation requests for ACTEMRA, COSENTYX, DUPIXENT, FASENRA, growth hormone, and other products require documented clinical benefit or response.
    • Do not assume an FDA-approved indication alone establishes coverage; submit the product-specific diagnosis, prior therapy, laboratory, molecular, and response evidence.

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: prior_auth

    Unsupported block type: documentation

    Ayvakit systemic mastocytosis platelet count
    Platelet thresholdGreater than or equal to 50,000/mcL
    Applies toSystemic mastocytosis
    Additional requirementIndolent or qualifying advanced systemic mastocytosis subtype
    Boniva injection osteoporosis T-score
    T-score thresholdAt or below -2.5
    Assessment sitesLumbar spine, femoral neck, or total hip
    Coverage contextPostmenopausal osteoporosis
    Boniva injection high-risk osteopenia T-score
    T-score rangeBetween -1.0 and -2.5
    Assessment sitesLumbar spine, femoral neck, or total hip
    Additional requirementHigh fracture risk with an additional qualifying circumstance
    Functional C1-INH for Cinryze
    Functional C1-INH thresholdLess than 50 percent of normal at baseline
    Applies toInitial Cinryze prophylaxis for type I or type II hereditary angioedema
    Additional laboratory requirementBaseline serum C4 below normal
    Camzyos maximal LV wall thickness
    Standard wall thicknessGreater than or equal to 15 mm
    Familial HCM thresholdAt least 13 mm
    Applies toInitial Camzyos therapy
    Camzyos peak LV outflow tract gradient
    LVOT gradientGreater than or equal to 50 mmHg
    MeasurementAt rest or after provocation
    Applies toInitial obstructive hypertrophic cardiomyopathy therapy
    Camzyos left ventricular ejection fraction
    LVEF thresholdGreater than or equal to 50 percent
    Applies toCamzyos continuation therapy
    Additional requirementAt least 8 months of established therapy
    Carglumic acid plasma ammonia
    Plasma ammonia thresholdGreater than or equal to 50 micromol/L
    Applies toAcute propionic or methylmalonic acidemia
    Additional requirementUse with other ammonia-lowering therapies
    C-reactive protein
    CRP thresholdElevated beyond the upper limit of normal for the reporting laboratory
    Applies toNon-radiographic axial spondyloarthritis
    Alternative evidenceSacroiliitis reported on magnetic resonance imaging
    Serum phosphorus for XLH
    Serum phosphorusBelow the normal range for age before XLH treatment
    Applies toInitial X-linked hypophosphatemia therapy
    Additional pathwayLow TmP/GFR or pathogenic PHEX variant
    TmP/GFR for XLH or TIO
    TmP/GFRBelow the normal range for age and gender before treatment
    Applies toXLH or tumor-induced osteomalacia
    Measurement timingBaseline, before treatment
    Serum ferritin for transfusion-related iron overload
    Ferritin threshold> 1,000 mcg/L before starting therapy
    Applies toTransfusion-related chronic iron overload
    Additional requirementBlood transfusions received at regular intervals
    Serum ferritin for non-transfusion-dependent thalassemia
    Ferritin threshold> 300 mcg/L before starting therapy
    Applies toNon-transfusion-dependent thalassemia
    ConditionChronic iron overload
    Doptelet chronic liver disease platelet threshold
    Platelet threshold<50 × 10^9/L
    Applies toThrombocytopenia associated with chronic liver disease
    Timing requirementProcedure scheduled 10 to 13 days after starting therapy
    Doptelet chronic ITP platelet threshold
    Platelet threshold<30,000/mcL
    Alternative threshold<50,000/mcL with increased bleeding risk
    Applies toInitial chronic immune thrombocytopenia therapy
    Dupixent asthma eosinophil threshold
    Eosinophil threshold≥150 cells/microliter
    TimingWithin the previous 6 weeks or before Dupixent or another monoclonal antibody
    Applies toInitial Dupixent asthma therapy
    Dupixent asthma pulmonary function thresholds
    FEV1 threshold<80% predicted, or <90% predicted for patients younger than 18
    FEV1/FVC threshold<0.8, or <0.9 for patients younger than 18
    Applies toUncontrolled asthma criteria
    Dupixent COPD eosinophil threshold
    Eosinophil threshold≥300 cells/microliter
    TimingWithin the previous 6 weeks or before Dupixent or another monoclonal antibody
    Applies toInitial Dupixent COPD therapy
    Dupixent EoE biopsy threshold
    Biopsy threshold≥15 intraepithelial eosinophils per high-power field
    Applies toEosinophilic esophagitis
    Additional requirementNo secondary cause of EoE
    Dupixent EoE weight threshold
    Weight threshold≥15 kg
    Applies toInitial Dupixent eosinophilic esophagitis therapy
    Additional requirementPrescription-strength PPI for at least 8 weeks
    Emgality migraine frequency
    Frequency threshold≥4 migraine headache days per month
    TimingBefore initiating a migraine-preventive medication
    Continuation requirementSignificant clinical benefit if already taking Emgality
    Fasenra asthma blood eosinophil count
    Eosinophil thresholdGreater than or equal to 150 cells per microliter
    TimingWithin the previous 6 weeks prior to Fasenra or another monoclonal antibody
    Applies toInitial Fasenra asthma therapy
    Fasenra asthma FEV1
    FEV1 thresholdLess than 80 percent predicted, or less than 90 percent predicted for patients younger than 18
    Applies toUncontrolled asthma criterion
    Alternative evidenceAsthma exacerbation or worsening during systemic corticosteroid taper
    Fasenra asthma FEV1/FVC
    FEV1/FVC thresholdLess than 0.80
    Applies toInitial Fasenra asthma therapy
    Clinical contextUncontrolled asthma criterion
    Febrile neutropenia risk
    Risk thresholdAt least 20 percent
    Applies toFebrile neutropenia risk from the chemotherapy regimen
    Coverage contextMyelosuppressive anticancer medication
    Renal dysfunction risk factor
    Renal thresholdCrCl less than 50 mL/min
    Applies toFebrile neutropenia risk factor
    Coverage contextFulphila chemotherapy-associated neutropenia prevention
    Liver dysfunction risk factor
    Bilirubin thresholdGreater than 2 mg/dL
    Applies toFebrile neutropenia risk factor
    Coverage contextFulphila chemotherapy-associated neutropenia prevention
    Gattex parenteral nutrition frequency
    Frequency threshold3 or more days per week
    Applies toParenteral nutrition
    Coverage contextInitial Gattex therapy for short bowel syndrome
    Pediatric growth-hormone stimulation testing
    Testing thresholdTwo tests less than 10 ng/mL
    Alternative pathwayOne test less than 10 ng/mL with a qualifying risk factor
    Applies toPediatric growth-hormone deficiency
    Adult growth-hormone stimulation testing
    Insulin peak≤5 mcg/L
    Arginine peak≤6.5 mcg/L
    Macrilen peak≤2.8 ng/mL with BMI ≤40
    Idiopathic short stature
    Baseline heightBelow the 1.2 percentile
    Alternative height measureHeight SDS less than -2.25
    Additional requirementQualifying growth velocity
    Growth disorder height criteria
    Baseline heightBelow the fifth percentile or applicable diagnosis-specific percentile
    Additional measureDiagnosis-specific growth-velocity thresholds
    Applies toGrowth-disorder coverage criteria
    The 18-year age restriction applies to both initial and continuation therapy
    Relapsing form of multiple sclerosis
    Clinically isolated syndromeIncluded as a relapsing form of multiple sclerosis
    Relapsing-remitting diseaseIncluded as a relapsing form of multiple sclerosis
    Active secondary progressive diseaseIncluded as a relapsing form of multiple sclerosis
    Autoantibody-positive SLE
    Antinuclear antibodiesPositive ANA supports the definition
    Anti-dsDNA antibodiesPositive anti-double-stranded DNA antibodies also support the definition
    Applies toAutoantibody-positive systemic lupus erythematosus
    WHO Group 1 PAH
    PAH categoryWorld Health Organization Group 1 pulmonary arterial hypertension
    Diagnostic confirmationRight-heart catheterization is required
    Applies toSpecified ambrisentan or bosentan coverage
    Relapsing MS
    Clinically isolated syndromeIncluded
    Relapsing-remitting diseaseIncluded
    Active secondary progressive diseaseIncluded
    Hereditary angioedema types I and II
    Type I HAEAssociated with C1-INH deficiency
    Type II HAEAssociated with C1-INH deficiency
    Initial prophylaxis laboratory findingsLow functional C1-INH and low C4
    NYHA class II or III
    NYHA class IIMild symptoms with moderate activity and some exercise limitations
    NYHA class IIINoticeable symptoms with minimal activity
    Comfort at restClass III patients are primarily comfortable at rest
    aTTP
    AbbreviationaTTP
    MeaningAcute acquired thrombotic thrombocytopenic purpura
    Treatment contextInpatient plasma exchange, immunosuppression, and Cablivi
    Non-radiographic axial spondyloarthritis
    ConditionNon-radiographic axial spondyloarthritis
    Inflammation evidenceElevated C-reactive protein or sacroiliitis on magnetic resonance imaging
    Coverage phaseInitial therapy criterion
    X-linked hypophosphatemia
    Baseline phosphorusBelow the normal range for age
    Additional laboratory pathwayBaseline TmP/GFR below the normal range for age and gender
    Genetic pathwayPathogenic PHEX variant confirmation
    HER2-negative disease
    IHC 0Included as HER2-negative disease
    IHC 1+Included as HER2-negative disease
    IHC 2+/ISH-negativeIncluded as HER2-negative disease
    NOH
    Primary autonomic failureQualifying cause of neurogenic orthostatic hypotension
    Dopamine beta-hydroxylase deficiencyQualifying cause of neurogenic orthostatic hypotension
    Non-diabetic autonomic dysfunctionQualifying cause of neurogenic orthostatic hypotension
    COPD
    AbbreviationCOPD
    MeaningChronic obstructive pulmonary disease
    Policy useA covered Dupixent indication with disease-specific clinical criteria
    CRSwNP
    AbbreviationCRSwNP
    MeaningChronic rhinosinusitis with nasal polyps
    Policy useA covered Dupixent indication
    EoE
    AbbreviationEoE
    MeaningEosinophilic esophagitis
    ConfirmationBiopsy with absence of a secondary cause
    AD
    AbbreviationAD
    MeaningAtopic dermatitis
    Policy useA covered Dupixent indication
    AFRS
    AbbreviationAFRS
    MeaningAllergic fungal rhinosinusitis
    Policy useA covered Dupixent indication with endoscopy or sinus CT criteria
    Chronic ITP
    AbbreviationChronic ITP
    MeaningChronic immune thrombocytopenia
    Policy useDoptelet indication
    EGFR mutation-positive NSCLC
    Exon 19Deletion mutations may qualify
    Exon 21L858R substitution mutations may qualify
    Other examplesL861Q, G719X, and S768I
    Mismatch repair and microsatellite status
    pMMR/MSSProficient mismatch repair/microsatellite-stable disease
    dMMR/MSI-HDeficient mismatch repair/microsatellite instability-high disease
    Applies toFruzaqla colorectal, rectal, or appendiceal cancer criteria
    RAS wild-type
    KRAS statusWild-type
    NRAS statusWild-type
    MeaningTumor or metastases are negative for KRAS and NRAS mutations
    RET-positive disease
    RET fusion-positiveQualifying RET fusion identified by appropriate molecular testing
    RET-mutation-positiveQualifying RET mutation identified by appropriate molecular testing
    Applies toSelected Gavreto cancer indications
    Sensitizing EGFR mutation-positive NSCLC
    DiseaseNon-small cell lung cancer
    Molecular findingActivating EGFR alteration detected by an approved test
    ExamplesExon 19 deletions, exon 21 L858R, L861Q, G719X, and S768I
    Growth hormone deficiency
    Stimulation testingDeficient growth-hormone stimulation testing
    Structural causesPituitary or hypothalamic disease
    Other supportRelevant hormone deficiencies or qualifying congenital, genetic, structural, surgical, radiation, traumatic, or tumor-related causes
    Small for gestational age
    Birth sizeBirth weight or length more than 2 standard deviations below the mean for gestational age and sex
    Catch-up growthInsufficient catch-up growth by age 2 to 4 years
    Applies toGrowth-hormone coverage criteria
    HER2/ERBB2 activating mutation
    ReceptorHuman epidermal growth factor receptor 2
    Alternative designationHER2 or ERBB2
    Coverage findingActivating mutation used for selected non-small cell lung cancer products
    Hereditary angioedema type I or II
    Type I HAEAssociated with C1-inhibitor deficiency
    Type II HAEAssociated with C1-inhibitor deficiency
    Supporting laboratory findingsLow functional C1-inhibitor and low serum C4 levels
    Molecular eligibility findings
    T315IMolecular eligibility finding
    BCR::ABL1 and ABL1Molecular eligibility findings
    FGFR1Molecular eligibility finding